Eloxx Pharmaceuticals Inc (ELOX)

NASDAQ
1.90
+0.05(+2.70%)
After Hours
1.92
+0.02(+1.05%)
- Real-time Data
  • Volume:
    1,690,246
  • Bid/Ask:
    1.91/1.95
  • Day's Range:
    1.82 - 1.92

ELOX Overview

Prev. Close
1.85
Day's Range
1.82-1.92
Revenue
-
Open
1.87
52 wk Range
1.34-6.76
EPS
-0.73
Volume
1,690,246
Market Cap
163.68M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,247,034
P/E Ratio
-
Beta
2.47
1-Year Change
-36.24%
Shares Outstanding
86,145,018
Next Earnings Date
Aug 11, 2021
What is your sentiment on Eloxx Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Eloxx Pharmaceuticals Inc News

Eloxx Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuyStrong Sell

Eloxx Pharmaceuticals Inc Company Profile

Eloxx Pharmaceuticals Inc Company Profile

Employees
25

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). It is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Its preclinical candidate pool consists of a library of novel ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.

Read More
  • Eloxx Pharmaceuticals Rajesh B Parekh  Director Buy 2,466,666 shares @ $1.35 $3,329,999.10 5/13/2021 $1.48
    0
    • yes my Greek Friend Alexandros insider trading . correct.
      0
      • Anyone?
        0
        • insider trading?
          0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.